Results 61 to 70 of about 6,549 (182)

Visualized Clinical‐Radiomics Model Based on Non‐Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms

Cancer Medicine, Volume 15, Issue 5, May 2026.
NCCT radiomics for surufatinib efficacy prediction in HM‐NENs. ABSTRACT Background Hepatic metastatic neuroendocrine neoplasms (HM‐NENs) have few treatment biomarkers and low survival rates. We created a clinical‐radiomics fusion model based on non‐contrast computed tomography (NCCT) to predict Surufatinib efficacy in HM‐NENs.
Miaomiao Feng, Man Zhao, Xiaoling Duan, Jiaojiao Hou, Qi Wang, Fei Yin   +5 more
wiley   +1 more source

Hepatic Radioembolization Complicated by Abscess [PDF]

Seminars in Interventional Radiology, 2011
Hepatic abscess is a rare complication of yttrium-90 radioembolization of hepatic tumors that most commonly occurs in patients with a history of biliary intervention. Patients usually present several weeks after therapy with pain, nausea, vomiting, and fever.
Neil, Mascarenhas, Robert K, Ryu, Riad, Salem   +2 more
openaire   +3 more sources

Outcomes of Hepatocellular Carcinoma involving the Portal Vein Main Trunk and/or the Inferior Vena Cava: Experience From a Multidisciplinary Liver Cancer Clinic

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Vascular invasion by hepatocellular carcinoma (HCC), particularly involving the main portal vein or inferior vena cava (IVC), is associated with poor prognosis. However, contemporary real‐world outcomes and the clinical benefit of liver‐directed therapies (LDT) in this setting are poorly defined.
I‐Chia Liu, Atif Zaheer, Chen Hu, Christopher Shubert, Kelly Lafaro, William R. Burns, Richard Burkhart, Jin He, Benjamin Philosophe, Jane Zorzi, Paige Griffith, Alexandra T. Strauss, Amy K. Kim, Robert Liddell, Kelvin Hong, Christos Georgiades, Robert Anders, Kiyoko Oshima, Elsa Hallab, Amol Narang, Won Jin Ho, Mark Yarchoan, Marina Baretti, Jeffrey Meyer   +23 more
wiley   +1 more source

Microspheres for radioembolization of liver malignancies [PDF]

Expert Review of Medical Devices, 2010
Microsphere radioembolization (RE) is applied increasingly in the management of patients with unresectable liver tumors. This type of internal radiation therapy deploys microspheres, loaded with the high-energy b-emitting radioisotope yttrium-90 (Y, E max = 2.280 MeV [I = 100.0%]), which are injected into the hepatic artery. The normal liver parenchyma
Maarten A D, Vente, Bernard A, Zonnenberg, J Frank W, Nijsen   +2 more
openaire   +2 more sources

Phase IIb Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 5, May 2026.
ABSTRACT This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intrahepatic cholangiocarcinoma (ICC) patients signed the informed consents.
Zu‐Yau Lin, Ming‐Lun Yeh, Po‐Cheng Liang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang   +8 more
wiley   +1 more source

90Y-/166Ho- ‘Radiation lobectomy’ for liver tumors induces abnormal morphology and impaired drainage of peritumor lymphatics

JHEP Reports
Background & Aims: High-dose unilobar radioembolization, or ‘radiation lobectomy’ (RL), is an induction therapy that achieves contralateral future liver remnant hypertrophy while simultaneously irradiating the tumor.
Daan Andel, Lotte van den Bent, Marnix Gerard Ernest Hendrik Lam, Maarten Leonard Johannes Smits, Isaac Quintus Molenaar, Joep de Bruijne, Miangela Marie Laclé, Onno Kranenburg, Inne Hildbrand Max Borel Rinkes, Jeroen Hagendoorn   +9 more
doaj   +1 more source

Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021

International Journal of Cancer, Volume 158, Issue 8, Page 2179-2185, 15 April 2026.
What's New? Liver metastasis is an indicator of life expectancy for patients with advanced uveal melanoma (UM). Data on anticipated survival time following the diagnosis of liver metastasis, however, is lacking. The present study analyzed long‐term survival among UM patients who lived three or more years after liver metastases were diagnosed.
Jona Laukhuf, Lisa Wiens, Gerd Grözinger, Helmut Dittmann, Karolin Thiel, Ulrike Leiter, Teresa Amaral, Lena Nanz, Lukas Flatz, Markus Reitmajer, Andrea Forschner   +10 more
wiley   +1 more source

Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025

Cancer Innovation, Volume 5, Issue 2, April 2026.
This review summarizes key breakthrough advances in hepatocellular carcinoma (HCC) reported in 2025 and presents a multidisciplinary management framework for HCC, integrating early diagnosis, microenvironment insights, and comprehensive therapeutic strategies spanning minimally invasive surgery, locoregional interventions, and systemic pharmacotherapy.
Bo Hu, Qiang Gao
wiley   +1 more source

Radiological Loco‐Regional Treatments for Cholangiocarcinoma: A Systematic Review of the Literature

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Cholangiocarcinoma (CCA) is the second most common primary liver cancer and is being diagnosed with increasing frequency worldwide. We performed a systematic review on radiofrequency (RFA), microwave (MWA), irreversible electroporation (IRE), trans‐arterial chemoembolization (TACE) and selective internal radiation therapy (SIRT) in CCA. Thirty‐
Dimitrios Pallas, Claudia Campani, Olivier Sutter, Pierre Nahon, Nathalie Ganne‐Carrié, Olivier Seror, Jean‐Charles Nault   +6 more
wiley   +1 more source

Evaluating the prognostic impact of inflammatory markers on treatment outcomes in patients with intrahepatic cholangiocarcinoma undergoing radioembolization

Diagnostic and Interventional Radiology
PURPOSE: Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive malignancy with limited treatment options, often diagnosed at advanced stages.
Sinan Sozutok, Ferhat Can Pişkin, Hüseyin Tuğsan Ballı, Berkay Dik   +3 more
doaj   +1 more source